Assessment of epi and genetic and clinical outcomes of resistance to bedaquiline

Full title: Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

On January 20th, 2021 RESIST-TB hosted a webinar to discuss updates on surveillance for resistance to new and repurposed drugs around the world. One of our speakers, Farzana Ismail, has now published their paper “Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to Bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.” Baseline bedaquiline resistance was seen in 3·8% of patients, while resistance developed during treatment in 16% of patients. The article demonstrates the importance of surveillance for resistance to the new drugs. Read Here.